The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 28, 2020

Filed:

Apr. 07, 2016
Applicants:

Suzhou Suncadia Biopharmaceuticals Co., Ltd., Suzhou, Jiangsu, CN;

Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu, CN;

Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, CN;

Inventors:

Jiajian Liu, Shanghai, CN;

Lianshan Zhang, Shanghai, CN;

Weikang Tao, Shanghai, CN;

Yayuan Fu, Shanghai, CN;

Ling Zhang, Shanghai, CN;

Dong Ma, Shanghai, CN;

Dongbing Cui, Shanghai, CN;

Yali Wang, Shanghai, CN;

Jianyan Xu, Shanghai, CN;

Jindong Liang, Shanghai, CN;

Ying Zhang, Shanghai, CN;

Guiyang Jiang, Shanghai, CN;

Junzhuan Qiu, Shanghai, CN;

Ziyong Sun, Shanghai, CN;

Jiping Zha, Shanghai, CN;

Jingping Wei, Shanghai, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61K 31/4745 (2006.01); A61K 31/537 (2006.01); A61P 35/00 (2006.01); A61K 38/08 (2019.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6849 (2017.08); A61K 31/4745 (2013.01); A61K 31/537 (2013.01); A61K 38/08 (2013.01); A61K 47/6817 (2017.08); A61K 47/6851 (2017.08); A61K 47/6857 (2017.08); A61K 47/6859 (2017.08); A61K 47/6861 (2017.08); A61K 47/6863 (2017.08); A61K 47/6889 (2017.08); A61P 35/00 (2018.01); C07K 16/2863 (2013.01); C07K 16/30 (2013.01); C07K 16/303 (2013.01); C07K 16/3023 (2013.01); C07K 16/3038 (2013.01); C07K 16/3046 (2013.01); C07K 16/464 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01); C07K 2317/94 (2013.01);
Abstract

Provided are an anti-c-Met antibody or an antigen binding fragment thereof, and an anti-c-Met antibody-cytotoxic drug conjugate, wherein the antibody or antigen binding fragment thereof is a chimeric antibody or a humanized antibody. Also provided are pharmaceutical compositions containing the humanized anti-c-Met antibody or antigen binding fragment thereof, the antibody-cytotoxic drug conjugate, or pharmaceutically acceptable salts or solvents thereof, that are used in the treatment of cancer.


Find Patent Forward Citations

Loading…